Columbus Macro LLC Buys 12,454 Shares of AstraZeneca PLC (NASDAQ:AZN)

Columbus Macro LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 61.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,692 shares of the company’s stock after purchasing an additional 12,454 shares during the period. Columbus Macro LLC’s holdings in AstraZeneca were worth $2,142,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. McClarren Financial Advisors Inc. raised its position in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the period. Capital Performance Advisors LLP purchased a new stake in AstraZeneca in the third quarter valued at about $28,000. Albion Financial Group UT increased its holdings in AstraZeneca by 68.9% in the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after buying an additional 248 shares during the period. Groupama Asset Managment boosted its holdings in AstraZeneca by 22.9% during the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after buying an additional 101,225 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in AstraZeneca in the 3rd quarter valued at about $45,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN stock opened at $69.86 on Tuesday. The firm has a market capitalization of $216.64 billion, a price-to-earnings ratio of 33.43, a PEG ratio of 1.18 and a beta of 0.46. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The business’s 50-day moving average price is $67.08 and its 200-day moving average price is $73.85. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.87 earnings per share. Equities research analysts forecast that AstraZeneca PLC will post 4.13 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.